Summary
Eighteen newborns (gestational age 28 to 42 weeks and post-natal age 0.5 to 44 days) suffering from convulsions not controlled by phenobarbital were treated with clonazepam 0.1 mg/kg (8 cases) or 0.2 mg/kg (10 cases) administered by slow intravenous infusion. The plasma half-lives in these ‘phenobarbital pretreated neonates’ were of the same order of magnitude as those reported in adults (20–43 h).
Post-natal age did affect clearance, which was 50–70% less than in adults and older children. At the end of the infusion period, plasma clonazepam ranged from 28 to 117 ng/ml in the 0.1 mg/kg group and from 99 to 380 ng/ml in the 0.2 mg/kg group. In the former an immediate therapeutic response was observed in 7 out of 8 cases, and in the latter a significant and somehow delayed effect on convulsion was present only in 6 cases. The data suggest that optimal therapeutic response might already have been achieved with the 0.1 mg/kg dose. Higher doses and toxic concentrations of clonazepam may be detrimental to complete control of seizures and may expose the newborn to an unnecessary risk of adverse events.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baruzzi A, Bodo B, Bossi L, Castelli D, Gerna M, Tognoni G, Zagnoni P (1977) Plasma levels of di-n-propylacetate and clonazepam in epileptic patient. Int J Clin Pharmacol Biopharm 15: 403–408
Congdon PJ, Forsythe WI (1980) Intravenous clonazepam in the treatment of status epilepticus in children. Epilepsia 21: 97–102
De Silva JAF, Puglisi CV, Munno N (1974) Determination of clonazepam and flunitrazepam in blood and urine by electron capture GLC. J Pharm Sci 63: 520–527
Dreifuss FE, Penry JK, Rose SW, Kupferberg HJ, Dyden P, Sato S (1975) Serum clonazepam concentrations in children with absence seizures. Neurology 25: 255–258
Dreifuss FE, Sato S (1982) Benzodiazepine:Clonazepam. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic drugs, II edn. Raven Press, New York, p 737
Gomeni R (1984) Pharm — an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comp Biol Med 14: 25–34
Kaplan SA, Alexander K, Jack ML, Puglisi CV, de Silva JAF, Lee TL, Weinfeld RE (1974) Pharmacokinetic profiles of clonazepam in dog and humans and of flunitrazepam in dog. J Pharm Sci 63: 527–532
Knop HJ, Edmunds LC, Van der Kleijn E (1979) Clinical pharmacokinetics of clonazepam. Excerpta Med Int Congr Series 501: 79–93
Morselli PL (1976) Pediatric clinical pharmacology: Routine monitoring or clinical trials? In: Gouveia B, Tognoni G, Van der Kleijn E (eds) Clinical pharmacy and clinical pharmacology. Elsevier/North Holland Biomed, Amsterdam, New York, pp 277–287
Morselli PL (1978) Clinical significance of monitoring plasma levels of benzodiazepine tranquilizers and antiepileptic drugs. In: Deniker P, Radouco-Thomas C, Villeneuve A (eds) Neuropsychopharmacology. Pergamon, Oxford New York, pp 877–888
Morselli PL, Franco-Morselli R, Bossi L (1980) Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet 5: 485–527
Pinder RM, Brogdem RN, Speight TM, Avery GS (1976) Clonazepam: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 12: 321–361
Syo O, Hvidberg EF, Naestoft J, Lund M (1975) Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man. Eur J Clin Pharmacol 81: 249–254
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
André, M., Boutroy, M.J., Dubruc, C. et al. Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures. Eur J Clin Pharmacol 30, 585–589 (1986). https://doi.org/10.1007/BF00542419
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542419